To include your compound in the COVID-19 Resource Center, submit it here.

OSI Pharmaceuticals updates OSI-774 Phase II data

In an ongoing Phase II trial of 56 patients with advanced,

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE